Pyrazole-amine compounds useful as kinase inhibitors

Abstract

The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where W, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p 38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.

1. A compound having the formula (I), 
       
         
           
           
               
               
           
         
       
       wherein:
 ring G is phenyl; 
 W is —CH(R 8 )NH—, wherein R 8  is hydrogen; 
 R 1  is aryl, or substituted aryl; 
 R 2  is hydrogen, alkyl, or substituted alkyl; 
 R 3  is hydrogen, C 1-4 alkyl, or substituted C 1-4 alkyl; 
 R 4  is hydrogen, C 1-4 alkyl, or substituted C 1-4 alkyl; 
 X is —(C═O)NH; 
 R 6  is heteroaryl or substituted heteroaryl; 
 m is 0; or a pharmaceutically-acceptable salt, hydrate, solvate, stereoisomer, or prodrug thereof. 
 
     
     
       2. A compound according to  claim 1 , having the formula, 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof, wherein ring Q is phenyl R 9  is selected from alkyl or substituted alkyl, trifluoromethyl, trifluoromethoxy, halogen, cyano, nitro, OH, OR 10,  SR 10 , and S(═O) 2 R 10 , wherein R 10  is lower alkyl; and n is 0, 1, 2 or 3. 
     
     
       3. The compound of  claim 2  wherein:
 Q is phenyl; 
 R 2  is lower alkyl, alkylamino; and 
 R 4  is lower alkyl. 
 
     
     
       4. The compound of  claim 1 , wherein:
 R 2  is hydrogen, C 1 –C 4  alkyl or substituted C 1 –C 4  alkyl; 
 R 4  is lower alkyl. 
 
     
     
       5. The compound of  claim 1 , wherein R 3  is hydrogen and R 4  is methyl. 
     
     
       6. The compound of  claim 4 , wherein R 3  is hydrogen and R 4  is methyl. 
     
     
       7. A compound according to  claim 2 , wherein R 6  form a heteroaryl; and/or pharmaceutically-acceptable salts, prodrugs, solvates, stereoisomer, and/or hydrates thereof. 
     
     
       8. A compound according to  claim 1 , wherein R 1  is selected from: 
       
         
           
           
               
               
           
         
         wherein R 30 , R 31 , R 32 , and R 33  are selected from hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, O(C 1-4 alkyl), nitro, and/or SO 2 CH 3 ; and 
         n is at each occurrence independently selected from 0–3; and/or pharmaceutically-acceptable salts, prodrugs, solvates, stereoisomer, and/or hydrates thereof. 
       
     
     
       9. A compound according to  claim 1 , wherein
 R 1  is optionally-substituted aryl; 
 R 2  is hydrogen or lower alkyl; 
 R 3  is hydrogen or methyl; and 
 R 4  is methyl; 
 and/or pharmaceutically-acceptable salts, prodrugs, solvates, stereoisomer, and/or hydrates thereof. 
 
     
     
       10. The compound of  claim 9 , wherein R 3  is hydrogen. 
     
     
       11. The compound of  claim 1 , wherein R 6  is a 5-membered heteroaryl which may be optionally substituted, R 3  is hydrogen, and R 4  is methyl. 
     
     
       12. The compound of  claim 11 , wherein R 6  is selected from the group consisting 
       
         
           
           
               
               
           
         
       
       wherein R 20  is hydrogen, lower alkyl or phenyl. 
     
     
       13. A pharmaceutical composition comprising at least one compound according to  claim 1  and a pharmaceutically-acceptable carrier or diluent.